A Multicentre Randomised Controlled Study Evaluating the Effect of a Standardised Education Programme on Quality of Life, Disease Severity, and Disease Knowledge in Patients with Moderate-To-Severe Psoriasis: The EDUPSO Study.


Journal

Dermatology (Basel, Switzerland)
ISSN: 1421-9832
Titre abrégé: Dermatology
Pays: Switzerland
ID NLM: 9203244

Informations de publication

Date de publication:
2022
Historique:
received: 03 05 2021
accepted: 18 10 2021
pubmed: 10 12 2021
medline: 9 7 2022
entrez: 9 12 2021
Statut: ppublish

Résumé

Psoriasis is a chronic inflammatory skin disease that has a profound effect on health-related quality of life (HRQoL). Patient education programmes may help patients to gain life-long control over their chronic disease. This multicentre randomised controlled study evaluated whether a standardised multidisciplinary education programme was beneficial to psoriasis patients. Adults with moderate-to-severe psoriasis were randomly assigned (1:1) to an intervention group to receive an educational programme or to a control group to receive usual care. Randomization was stratified by previous treatment history. The primary outcome was HRQoL, assessed by scoring the Skindex-29 domains emotion, symptom, and functioning. Psoriasis severity was assessed using the psoriasis area severity index (PASI). Levels of perceived stress, patient knowledge about psoriasis, and patient satisfaction were also assessed. Follow-up evaluations were performed at 3, 6, and 12 months. A total 142 patients formed the intention-to-treat population: 70 in the control group and 72 in the intervention group. Skindex component scores and the PASI were significantly lower at 3, 6, and 12 months as compared to baseline in both groups, but no significant differences were found between the groups. Knowledge about psoriasis improved significantly during follow-up amongst patients from the intervention group compared to controls (68% of correct answers vs. 56%; p < 0.01). Patient satisfaction with psoriasis management and treatment was also better in the intervention group. The standardised education programme did not improve HRQoL and disease severity in psoriasis, but led to a significant improvement in patient knowledge about the disease and increased patient satisfaction.

Sections du résumé

BACKGROUND BACKGROUND
Psoriasis is a chronic inflammatory skin disease that has a profound effect on health-related quality of life (HRQoL). Patient education programmes may help patients to gain life-long control over their chronic disease.
OBJECTIVE OBJECTIVE
This multicentre randomised controlled study evaluated whether a standardised multidisciplinary education programme was beneficial to psoriasis patients.
METHODS METHODS
Adults with moderate-to-severe psoriasis were randomly assigned (1:1) to an intervention group to receive an educational programme or to a control group to receive usual care. Randomization was stratified by previous treatment history. The primary outcome was HRQoL, assessed by scoring the Skindex-29 domains emotion, symptom, and functioning. Psoriasis severity was assessed using the psoriasis area severity index (PASI). Levels of perceived stress, patient knowledge about psoriasis, and patient satisfaction were also assessed. Follow-up evaluations were performed at 3, 6, and 12 months.
RESULTS RESULTS
A total 142 patients formed the intention-to-treat population: 70 in the control group and 72 in the intervention group. Skindex component scores and the PASI were significantly lower at 3, 6, and 12 months as compared to baseline in both groups, but no significant differences were found between the groups. Knowledge about psoriasis improved significantly during follow-up amongst patients from the intervention group compared to controls (68% of correct answers vs. 56%; p < 0.01). Patient satisfaction with psoriasis management and treatment was also better in the intervention group.
CONCLUSIONS CONCLUSIONS
The standardised education programme did not improve HRQoL and disease severity in psoriasis, but led to a significant improvement in patient knowledge about the disease and increased patient satisfaction.

Identifiants

pubmed: 34883480
pii: 000520289
doi: 10.1159/000520289
doi:

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

630-639

Informations de copyright

© 2021 S. Karger AG, Basel.

Auteurs

Fatma Jendoubi (F)

Department of Dermatology, Toulouse University, Hôpital Larrey, Toulouse, France, jendoubi.f@chu-toulouse.fr.

Stefana Balica (S)

Department of Dermatology, Toulouse University, Hôpital Larrey, Toulouse, France.

Marie Aleth Richard (MA)

Department of Dermatology, Marseille University, Marseille, France.

Christine Chiaverini (C)

Department of Dermatology, Nice University and l'Archet II Hospital, Nice, France.

Claire Bernier (C)

Department of Dermatology, Nantes University Hospital, Nantes, France.

Nathalie Quiles (N)

Department of Dermatology, Saint Joseph Hospital, Marseille, France.

Herve Bachelez (H)

Department of Dermatology, Saint Louis Hospital, APHP, Université de Paris, Paris, France.

Marie Beylot-Barry (M)

Dermatology, CHU Bordeaux and Bordeaux University, Bordeaux, France.

Stéphanie Mallet (S)

Department of Dermatology, Marseille University, Marseille, France.

Catherine Goujon (C)

Immuno-allergology Department, Lyon, France.

Josiane Parier (J)

Department of Dermatology, Saint Louis Hospital, APHP, Université de Paris, Paris, France.

Laurent Misery (L)

Dermatology, CHU Brest and Bretagne University, Brest, France.

Florence Carrere (F)

STATITEC, Labège, France.

Valérie Lauwers-Cances (V)

Department of Epidemiology and Biostatistics, Toulouse University Hospital, Toulouse, France.

Carle Paul (C)

Department of Dermatology, Toulouse University, Hôpital Larrey, Toulouse, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH